WeMed

WeMed is a Beijing-based Chinese medical device company focused on interventional diagnosis and treatment solutions rather than therapeutics. The company develops and commercializes digital subtraction angiography systems, mobile and surgical C-arm X-ray systems, AI-enabled imaging platforms, and interventional surgical robots for cardiovascular and neurovascular procedures. Its flagship ETcath interventional robotic system received NMPA approval in March 2025, while the broader product portfolio is marketed domestically and internationally. WeMed positions itself as a high-end domestic medtech challenger in interventional imaging and robotics, with products exported to more than 40 countries and regions. The company also provides clinical workflow, academic support, and department-level interventional solutions.